Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7025663 | 0.85 | SLC6A2 (0.32) | CETPSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1244525 | 0.77 | CETP (0.35) | CETP | |
| SCHEMBL1900064 | 0.76 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL993383 | 0.73 | SLC6A2 (0.42) | CETPSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL994091 | 0.69 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL993681 | 0.68 | CETP (0.36) | CETP | |
| SCHEMBL1901254 | 0.67 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1900062 | 0.67 | CETP (0.58) | CETPSLC6A2SLC6A4 | |
| SCHEMBL993382 | 0.67 | CETP (0.49) | CETPSLC6A2SLC6A4 | |
| SCHEMBL992461 | 0.66 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885CXCR4 1942/4885SLC6A2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.